Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Helena Yu

Photo of Helena Yu
Title(s)Associate Physician, Pediatrics
SchoolVc-health Sciences-schools
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Keck School of Medicine of USC, Los Angeles, CAMD05/2017Medicine
    UCSF Benioff Children's Hospital Oakland, Oakland, CA06/2020Pediatrics
    UCSD/Rady Children's Hospital, San Diego, CA07/2023Pediatric Hematology/Oncology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer. Clin Cancer Res. 2025 Nov 14; 31(22):4698-4706. Rimner A, Lok BH, Gelblum DY, Kotecha RR, Shin JY, LaPlant Q, Shepherd AF, Shaverdian N, Simone CB, Ng VJ, Ionescu A, Yu HA, Daly R, Offin MD, Yorke ED, Ginsberg MS, Zhang Z, Wu AJ, Rudin CM. PMID: 40880183.
      View in: PubMed   Mentions:
    2. Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer. JCO Precis Oncol. 2025 Sep; 9:e2500631. Chen MF, Gomez D, Yu HA. PMID: 40929616.
      View in: PubMed   Mentions:
    3. Proteostasis disruption in inherited bone marrow failure syndromes. Blood. 2025 Jul 17; 146(3):304-317. Yu H, Signer RAJ. PMID: 40089997; PMCID: PMC12333235.
      View in: PubMed   Mentions:
    4. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precis Oncol. 2025 Jun; 9:e2400818. Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, Le X, Cho BC, Yoneshima Y, Ambrose H, Cavazzina R, Tang KH, Lau J, Yu HA. PMID: 40466026.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. J Clin Oncol. 2025 Jul 20; 43(21):2387-2397. Piotrowska Z, Passaro A, Nguyen D, Ruiter G, Soo RA, Ho-Fun Lee V, Velcheti V, Tan DS, Lee SH, Kim SH, Wrangle J, Yang JC, Daga H, Juan Vidal OJ, Spira AI, Fernandez-Hinojal G, Kim SW, Umemura S, Provencio Pulla M, Keeton EK, Yang ZS, Li S, Xu ZC, Jones JA, Yu HA, REZILIENT1 Investigators. PMID: 40450572.
      View in: PubMed   Mentions:
    6. Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity. JACC CardioOncol. 2025 Jun; 7(4):325-344. El-Rayes M, Nardi Agmon I, Yu C, Osataphan N, Yu HA, Hope A, Sacher A, Yu AF, Abdel-Qadir H, Thavendiranathan P. PMID: 40537184; PMCID: PMC12228138.
      View in: PubMed   Mentions:
    7. Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precis Oncol. 2025 May; 9:e2500047. Chen MF, Jeng MY, Ma J, Agrawal P, Dunne E, Boe LA, Kris MG, Huang J, Veeraraghavan H, Gomez D, Yu HA. PMID: 40373257; PMCID: PMC12088374.
      View in: PubMed   Mentions:
    8. Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity. bioRxiv. 2025 May 10. Zatzman M, Quintanal-Villalonga A, Salehi S, Ceglia N, Lee JJ, Pupo AN, Falcon CJ, Rusk N, Masilionis I, Chaudhary O, Manoj P, Chaligne R, McPherson A, Rudin CM, Shah SP, Yu HA. PMID: 40654861; PMCID: PMC12248098.
      View in: PubMed   Mentions:
    9. Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States. J Thorac Oncol. 2025 Sep; 20(9):1268-1278. Sabari JK, Yu HA, Mahadevia PJ, Liu Y, Demirdjian L, Chen YH, Wang X, Passaro A. PMID: 40320171.
      View in: PubMed   Mentions:
    10. Responsiveness of different MET tumour alterations to type I and type II MET inhibitors. Clin Transl Med. 2025 May; 15(5):e70338. Murciano-Goroff YR, Foglizzo V, Chang J, Rekhtman N, Sisk AE, Gibson J, Judka L, Clemens K, Roa P, Ahmed SS, Bremer NV, Binaco CL, Muzungu SK, Rodriguez E, Merrill M, Sgroe E, Repetto M, Stadler ZK, Berger MF, Yu HA, Toska E, Kannan S, Verma CS, Drilon A, Cocco E. PMID: 40437874; PMCID: PMC12120261.
      View in: PubMed   Mentions:
    11. Chromothripsis-Mediated Small Cell Lung Carcinoma. Cancer Discov. 2025 Jan 13; 15(1):83-104. Rekhtman N, Tischfield SE, Febres-Aldana CA, Lee JJ, Chang JC, Herzberg BO, Selenica P, Woo HJ, Vanderbilt CM, Yang SR, Xu F, Bowman AS, da Silva EM, Noronha AM, Mandelker DL, Mehine M, Mukherjee S, Blanco-Heredia J, Orgera JJ, Nanjangud GJ, Baine MK, Aly RG, Sauter JL, Travis WD, Savari O, Moreira AL, Falcon CJ, Bodd FM, Wilson CE, Sienty JV, Manoj P, Sridhar H, Wang L, Choudhury NJ, Offin M, Yu HA, Quintanal-Villalonga A, Berger MF, Ladanyi M, Donoghue MTA, Reis-Filho JS, Rudin CM. PMID: 39185963; PMCID: PMC11726019.
      View in: PubMed   Mentions:
    12. A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases. Oncol Ther. 2025 Mar; 13(1):17-30. Johnson ML, Lin JJ, Boire A, Khandekar MJ, Yu HA. PMID: 39695026; PMCID: PMC11880489.
      View in: PubMed   Mentions:
    13. Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets. Clin Cancer Res. 2024 Sep 03; 30(17):3812-3823. Chen MF, Yang SR, Tao JJ, Desilets A, Diamond EL, Wilhelm C, Rosen E, Gong Y, Mullaney K, Torrisi J, Young RJ, Somwar R, Yu HA, Kris MG, Riely GJ, Arcila ME, Ladanyi M, Donoghue MTA, Rosen N, Yaeger R, Drilon A, Murciano-Goroff YR, Offin M. PMID: 38922339; PMCID: PMC11371517.
      View in: PubMed   Mentions:
    14. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal Transduct Target Ther. 2024 07 26; 9(1):189. Quintanal-Villalonga A, Kawasaki K, Redin E, Uddin F, Rakhade S, Durani V, Sabet A, Shafer M, Karthaus WR, Zaidi S, Zhan YA, Manoj P, Sridhar H, Kinyua D, Zhong H, Mello BP, Ciampricotti M, Bhanot UK, Linkov I, Qiu J, Patel RA, Morrissey C, Mehta S, Barnes J, Haffner MC, Socci ND, Koche RP, de Stanchina E, Molina-Pinelo S, Salehi S, Yu HA, Chan JM, Rudin CM. PMID: 39054323; PMCID: PMC11272780.
      View in: PubMed   Mentions:
    15. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Oct; 42(28):3339-3349. Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman AS, Begüm Bektas A, Bradic M, Kang W, Chan E, Gogia P, Manova-Todorova K, Mata DA, Egger JV, Rizvi H, Socci ND, Kelly DW, Rosiek E, Meng F, Tam G, Fan N, Drilon A, Yu HA, Riely GJ, Rekhtman N, Quintanal Villalonga Á, Dogan S, Bhanot U, Gönen M, Loomis B, Hellmann MD, Schoenfeld AJ, Ladanyi M, Rudin CM, Vanderbilt CM. PMID: 39038258; PMCID: PMC11600405.
      View in: PubMed   Mentions:
    16. Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2024 Aug 10; 42(23):2727-2730. Jeng MY, Yu HA. PMID: 38941569.
      View in: PubMed   Mentions:
    17. Concurrent rhabdomyosarcoma and neuroblastoma in an infant with Costello syndrome. Pediatr Blood Cancer. 2024 Aug; 71(8):e31084. Yu H, Sridhar S, Mo J, Bird LM, Elster J. PMID: 38753430.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 Apr; 8:e2300454. Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. PMID: 38591867; PMCID: PMC10896470.
      View in: PubMed   Mentions:
    19. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol. 2024 May; 20(15):969-980. Mok T, Jänne PA, Nishio M, Novello S, Reck M, Steuer C, Wu YL, Fougeray R, Fan PD, Meng J, Sternberg DW, Esker S, Yu HA. PMID: 38095056.
      View in: PubMed   Mentions:
    20. Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC. JTO Clin Res Rep. 2023 Dec; 4(12):100607. Imber BS, Sehgal R, Saganty R, Reiner AS, Ilica AT, Miao E, Li BT, Riely GJ, Yu HA, Panageas KS, Young RJ, Pike LRG, Moss NS. PMID: 38124791; PMCID: PMC10730363.
      View in: PubMed   Mentions:
    21. The Promise and Limitations of Neoadjuvant Immune-Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer. Cancer Discov. 2023 11 01; 13(11):2306-2309. Cooper AJ, Yu HA. PMID: 37909090.
      View in: PubMed   Mentions:
    22. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 12 10; 41(35):5363-5375. Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA. PMID: 37689979; PMCID: PMC10713116.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCTClinical Trials
    23. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat Commun. 2023 08 17; 14(1):4980. Skakodub A, Walch H, Tringale KR, Eichholz J, Imber BS, Vasudevan HN, Li BT, Moss NS, Hei Yu KK, Mueller BA, Powell S, Razavi P, Yu HA, Reis-Filho JS, Gomez D, Schultz N, Pike LRG. PMID: 37591896; PMCID: PMC10435547.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    24. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. 2023 08 02; 15(707):eadf7006. Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus WR, Zaidi S, Zhan YA, Manoj P, Sridhar H, Shah NS, Chow A, Bhanot UK, Linkov I, Asher M, Yu HA, Qiu J, de Stanchina E, Patel RA, Morrissey C, Haffner MC, Koche RP, Sawyers CL, Rudin CM. PMID: 37531417; PMCID: PMC10777207.
      View in: PubMed   Mentions:
    25. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. J Clin Oncol. 2023 09 10; 41(26):4218-4225. Piotrowska Z, Tan DS, Smit EF, Spira AI, Soo RA, Nguyen D, Lee VH, Yang JC, Velcheti V, Wrangle JM, Socinski MA, Koczywas M, Janik JE, Jones J, Yu HA. PMID: 37384848.
      View in: PubMed   Mentions:
    26. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clin Cancer Res. 2023 06 01; 29(11):2123-2130. Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. PMID: 36913537; PMCID: PMC10493186.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    27. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol. 2023 Jun; 19(19):1319-1329. Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Jänne PA. PMID: 37212796.
      View in: PubMed   Mentions:
    28. Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas. Clin Cancer Res. 2023 04 14; 29(8):1423-1428. Elkrief A, Makhnin A, Moses KA, Ahn LS, Preeshagul IR, Iqbal AN, Hayes SA, Plodkowski AJ, Paik PK, Ladanyi M, Kris MG, Riely GJ, Michor F, Yu HA. PMID: 36729110; PMCID: PMC10150646.
      View in: PubMed   Mentions:
    29. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023 01 09; 13(1):98-113. Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC, Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DAE, Kurian N, Cantarini M, Jänne PA. PMID: 36264123; PMCID: PMC9827108.
      View in: PubMed   Mentions:
    30. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. J Thorac Oncol. 2023 04; 18(4):463-475. Choudhury NJ, Marra A, Sui JSY, Flynn J, Yang SR, Falcon CJ, Selenica P, Schoenfeld AJ, Rekhtman N, Gomez D, Berger MF, Ladanyi M, Arcila M, Rudin CM, Riely GJ, Kris MG, Heller G, Reis-Filho JS, Yu HA. PMID: 36494075; PMCID: PMC10249779.
      View in: PubMed   Mentions:
    31. Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 05; 165(5):1682-1693.e3. Lengel HB, Zheng J, Tan KS, Liu CC, Park BJ, Rocco G, Adusumilli PS, Molena D, Yu HA, Riely GJ, Bains MS, Rusch VW, Kris MG, Chaft JE, Li BT, Isbell JM, Jones DR. PMID: 36528430; PMCID: PMC10085825.
      View in: PubMed   Mentions:
    32. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med. 2022 11; 28(11):2353-2363. Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, Chaft JE, Jayakumaran G, Rose Brannon A, Benayed R, Zehir A, Donoghue M, Schultz N, Chakravarty D, Kundra R, Madupuri R, Murciano-Goroff YR, Tu HY, Xu CR, Martinez A, Wilhelm C, Galle J, Daly B, Yu HA, Offin M, Hellmann MD, Lito P, Arbour KC, Zauderer MG, Kris MG, Ng KK, Eng J, Preeshagul I, Victoria Lai W, Fiore JJ, Iqbal A, Molena D, Rocco G, Park BJ, Lim LP, Li M, Tong-Li C, De Silva M, Chan DL, Diakos CI, Itchins M, Clarke S, Pavlakis N, Lee A, Rekhtman N, Chang J, Travis WD, Riely GJ, Solit DB, Gonen M, Rusch VW, Rimner A, Gomez D, Drilon A, Scher HI, Shah SP, Berger MF, Arcila ME, Ladanyi M, Levine RL, Shen R, Razavi P, Reis-Filho JS, Jones DR, Rudin CM, Isbell JM, Li BT. PMID: 36357680; PMCID: PMC10338177.
      View in: PubMed   Mentions:
    33. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clin Cancer Res. 2022 11 01; 28(21):4702-4713. Febres-Aldana CA, Chang JC, Ptashkin R, Wang Y, Gedvilaite E, Baine MK, Travis WD, Ventura K, Bodd F, Yu HA, Quintanal-Villalonga A, Lai WV, Egger JV, Offin M, Ladanyi M, Rudin CM, Rekhtman N. PMID: 35792876; PMCID: PMC9623236.
      View in: PubMed   Mentions:
    34. Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2022 Sep 23; 13(1):5579. Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. PMID: 36151107; PMCID: PMC9508237.
      View in: PubMed   Mentions:
    35. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. JCO Precis Oncol. 2022 08; 6:e2200088. Sato H, Kubota D, Qiao H, Jungbluth A, Rekhtman N, Schoenfeld AJ, Yu HA, Riely GJ, Toyooka S, Lovly CM, Paik P, Ladanyi M, Fan PD. PMID: 35952318; PMCID: PMC9384924.
      View in: PubMed   Mentions:
    36. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328. Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z. PMID: 35637759; PMCID: PMC9142556.
      View in: PubMed   Mentions: 26  
    37. Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer. Cancer Discov. 2022 04 01; 12(4):1002-1021. Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, Shakri AR, Zhong TJ, Scholze H, Lagos GG, Mela A, Manova-Todorova K, de Stanchina E, Ferrando AA, Mendelsohn C, Canoll P, Yu HA, Paik PK, Saqi A, Shu CA, Kris MG, Massague J, Acharyya S. PMID: 35078784; PMCID: PMC8983473.
      View in: PubMed   Mentions:
    38. Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Sci Transl Med. 2022 03 30; 14(638):eabc7480. Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC. PMID: 35353542; PMCID: PMC9516479.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    39. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. Br J Cancer. 2022 04; 126(6):889-898. Murciano-Goroff YR, Pak T, Mondaca S, Flynn JR, Montecalvo J, Rekhtman N, Halpenny D, Plodkowski AJ, Wu SL, Kris MG, Paik PK, Riely GJ, Yu HA, Rudin CM, Hellmann MD, Land JD, Buie LW, Heller G, Lito P, Yaeger R, Drilon A, Liu D, Li BT, Offin M. PMID: 34963703; PMCID: PMC8927094.
      View in: PubMed   Mentions:
    40. Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discov. 2021 12 01; 11(12):3028-3047. Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, Ray-Kirton J, Tischfield SE, Egger J, Bhanot UK, Linkov I, Asher M, Sinha S, Silber J, Iacobuzio-Donahue CA, Roehrl MH, Hollmann TJ, Yu HA, Qiu J, de Stanchina E, Baine MK, Rekhtman N, Poirier JT, Loomis B, Koche RP, Rudin CM, Sen T. PMID: 34155000; PMCID: PMC9437746.
      View in: PubMed   Mentions:
    41. Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO Clin Res Rep. 2022 Jan; 3(1):100256. Arbour KC, Manchado E, Bott MJ, Ahn L, Tobi Y, Ni AA, Yu HA, Shannon A, Ladanyi M, Perron V, Ginsberg MS, Johnson A, Holodny A, Kris MG, Rudin CM, Lito P, Rosen N, Lowe S, Riely GJ. PMID: 34984405; PMCID: PMC8693267.
      View in: PubMed   Mentions:
    42. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. J Hematol Oncol. 2021 10 16; 14(1):170. Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, Egger JD, Bhanot UK, Linkov I, Asher M, Roehrl MH, Ventura K, Qiu J, de Stanchina E, Chang JC, Rekhtman N, Houck-Loomis B, Koche RP, Yu HA, Sen T, Rudin CM. PMID: 34656143; PMCID: PMC8520275.
      View in: PubMed   Mentions:
    43. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022 01; 12(1):74-89. Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. PMID: 34548309; PMCID: PMC9401524.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCTClinical Trials
    44. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021 09 13; 39(9):1245-1261.e6. Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. PMID: 34388376; PMCID: PMC8440494.
      View in: PubMed   Mentions:
    45. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 11; 22(6):601-606. Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. PMID: 34389237; PMCID: PMC10470656.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    46. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat Commun. 2021 06 18; 12(1):3770. Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, Sadowska J, Murphy BJ, Baldi T, Johnson I, Ptashkin R, Hasan M, Srinivasan P, Rema AB, Rijo I, Agarunov A, Won H, Perera D, Brown DN, Samoila A, Jing X, Gedvilaite E, Yang JL, Stephens DP, Dix JM, DeGroat N, Nafa K, Syed A, Li A, Lebow ES, Bowman AS, Ferguson DC, Liu Y, Mata DA, Sharma R, Yang SR, Bale T, Benhamida JK, Chang JC, Dogan S, Hameed MR, Hechtman JF, Moung C, Ross DS, Vakiani E, Vanderbilt CM, Yao J, Razavi P, Smyth LM, Chandarlapaty S, Iyer G, Abida W, Harding JJ, Krantz B, O'Reilly E, Yu HA, Li BT, Rudin CM, Diaz L, Solit DB, Arcila ME, Ladanyi M, Loomis B, Tsui D, Berger MF, Zehir A, Benayed R. PMID: 34145282; PMCID: PMC8213710.
      View in: PubMed   Mentions:
    47. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2021 06 17; 12(1):3697. Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. PMID: 34140482; PMCID: PMC8211846.
      View in: PubMed   Mentions:
    48. Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precis Oncol. 2021; 5. Choudhury NJ, Makhnin A, Tobi YY, Daly RM, Preeshagul IR, Iqbal AN, Ahn LS, Hayes SA, Heller G, Kris MG, Riely GJ, Yu HA. PMID: 34250398; PMCID: PMC8232442.
      View in: PubMed   Mentions:
    49. Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. J Mol Diagn. 2021 06; 23(6):742-752. Bale TA, Yang SR, Solomon JP, Nafa K, Middha S, Casanova J, Sadowska J, Skakodub A, Ahmad H, Yu HA, Riely GJ, Kris MG, Chandarlapaty S, Rosenblum MK, Gavrilovic I, Karajannis MA, Pentsova E, Miller A, Boire A, Mellinghoff I, Berger MF, Zehir A, Ladanyi M, Benayed R, Arcila ME. PMID: 33781965; PMCID: PMC8207471.
      View in: PubMed   Mentions:
    50. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clin Cancer Res. 2021 05 15; 27(10):2920-2927. Choudhury NJ, Schoenfeld AJ, Flynn J, Falcon CJ, Rizvi H, Rudin CM, Kris MG, Arcila ME, Heller G, Yu HA, Ladanyi M, Riely GJ. PMID: 33685865; PMCID: PMC8127357.
      View in: PubMed   Mentions:
    51. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 04 15; 27(8):2209-2215. Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ. PMID: 33558425; PMCID: PMC8771577.
      View in: PubMed   Mentions:
    52. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol. 2021 01 30; 23(1):134-143. Yang TJ, Wijetunga NA, Yamada J, Wolden S, Mehallow M, Goldman DA, Zhang Z, Young RJ, Kris MG, Yu HA, Seidman AD, Gavrilovic IT, Lin A, Santomasso B, Grommes C, Piotrowski AF, Schaff L, Stone JB, DeAngelis LM, Boire A, Pentsova E. PMID: 32592583; PMCID: PMC7850116.
      View in: PubMed   Mentions:
    53. Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021; 5. Luo J, Makhnin A, Tobi Y, Ahn L, Hayes SA, Iqbal A, Ng K, Arcila ME, Riely GJ, Kris MG, Yu HA. PMID: 34250388; PMCID: PMC8232136.
      View in: PubMed   Mentions:
    54. Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply. JAMA Oncol. 2020 12 01; 6(12):1983. Schoenfeld AJ, Yu HA. PMID: 33119042.
      View in: PubMed   Mentions:
    55. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021 02 15; 27(4):992-1002. Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. PMID: 33046516; PMCID: PMC8793125.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    56. Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. J Thorac Oncol. 2021 01; 16(1):113-126. Sato H, Offin M, Kubota D, Yu HA, Wilhelm C, Toyooka S, Somwar R, Kris MG, Ladanyi M. PMID: 33038514; PMCID: PMC7775889.
      View in: PubMed   Mentions:
    57. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. JAMA Oncol. 2020 07 01; 6(7):1048-1054. Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, Tobi Y, Heller G, Ahn L, Hayes SA, Young RJ, Arcila ME, Berger M, Chaft JE, Ladanyi M, Riely GJ, Kris MG. PMID: 32463456; PMCID: PMC7256866.
      View in: PubMed   Mentions:
    58. Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020 Jun; 17(6):382. Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Sen T, Rudin CM. PMID: 32203275.
      View in: PubMed   Mentions:
    59. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov. 2020 05; 10(5):674-687. Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. PMID: 32213539; PMCID: PMC7196485.
      View in: PubMed   Mentions: 133     Fields:    Translation:HumansCells
    60. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020 06; 17(6):360-371. Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Sen T, Rudin CM. PMID: 32152485; PMCID: PMC7397755.
      View in: PubMed   Mentions:
    61. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clin Cancer Res. 2020 06 01; 26(11):2654-2663. Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, Davare MA, Shinde U, Pe'er D, Rekhtman N, Kris MG, Somwar R, Riely GJ, Ladanyi M, Yu HA. PMID: 31911548; PMCID: PMC7448565.
      View in: PubMed   Mentions:
    62. The Evolving Landscape of Resistance to Osimertinib. J Thorac Oncol. 2020 01; 15(1):18-21. Schoenfeld AJ, Yu HA. PMID: 31864549.
      View in: PubMed   Mentions:
    63. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. J Clin Oncol. 2019 12 20; 37(36):3546-3555. Osorio JC, Arbour KC, Le DT, Durham JN, Plodkowski AJ, Halpenny DF, Ginsberg MS, Sawan P, Crompton JG, Yu HA, Namakydoust A, Nabet BY, Chaft JE, Riely GJ, Rizvi H, Diaz LA, Hellmann MD. PMID: 31675272; PMCID: PMC7194449.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    64. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer. 2019 12 15; 125(24):4380-4387. Offin M, Feldman D, Ni A, Myers ML, Lai WV, Pentsova E, Boire A, Daras M, Jordan EJ, Solit DB, Arcila ME, Jones DR, Isbell JM, Beal K, Young RJ, Rudin CM, Riely GJ, Drilon A, Tabar V, DeAngelis LM, Yu HA, Kris MG, Li BT. PMID: 31469421; PMCID: PMC6891113.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    65. Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta Oncol. 2019 Nov; 58(11):1634-1639. Mondaca S, Offin M, Borsu L, Myers M, Josyula S, Makhnin A, Shen R, Riely GJ, Rudin CM, Ladanyi M, Yu HA, Li BT, Arcila ME. PMID: 31347936; PMCID: PMC7480496.
      View in: PubMed   Mentions:
    66. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. J Thorac Oncol. 2019 11; 14(11):1982-1988. Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, Ganesan S. PMID: 31254668; PMCID: PMC8080261.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    67. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. J Thorac Oncol. 2019 10; 14(10):1784-1793. Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA. PMID: 31228622; PMCID: PMC6764905.
      View in: PubMed   Mentions:
    68. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. J Natl Cancer Inst. 2019 Jun 01; 111(6):575-583. Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT. PMID: 30496436; PMCID: PMC6579739.
      View in: PubMed   Mentions:
    69. Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. JCO Precis Oncol. 2019; 3. Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M. PMID: 31157314; PMCID: PMC6541452.
      View in: PubMed   Mentions:
    70. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harb Mol Case Stud. 2019 04; 5(2). Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, Riely GJ. PMID: 30936194; PMCID: PMC6549573.
      View in: PubMed   Mentions:
    71. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol. 2019 05; 14(5):802-815. Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M. PMID: 30831205; PMCID: PMC6486868.
      View in: PubMed   Mentions:
    72. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. PMID: 30550363; PMCID: PMC7001776.
      View in: PubMed   Mentions: 263     Fields:    Translation:Humans
    73. EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2018 Nov; 2:1-13. Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale RB, Otterson GA, Papadimitrakopoulou V, Langer CJ, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA. PMID: 35135111.
      View in: PubMed   Mentions: 7     Fields:    
    74. Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO Precis Oncol. 2018; 2. Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA. PMID: 30957057; PMCID: PMC6447364.
      View in: PubMed   Mentions:
    75. ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers. Clin Cancer Res. 2018 11 15; 24(22):5499-5501. Fan PD, Yu HA. PMID: 30135146.
      View in: PubMed   Mentions:
    76. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clin Lung Cancer. 2018 11; 19(6):518-530.e7. Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, Camidge DR, Harding TC, Lanman RB, Simmons AD. PMID: 30279111.
      View in: PubMed   Mentions:
    77. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A. 2018 06 26; 115(26):E6030-E6038. Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M. PMID: 29875142; PMCID: PMC6042104.
      View in: PubMed   Mentions:
    78. Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:726-739. Yu HA, Planchard D, Lovly CM. PMID: 30231382; PMCID: PMC10172876.
      View in: PubMed   Mentions:
    79. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res. 2018 07 01; 24(13):3108-3118. Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M. PMID: 29530932; PMCID: PMC6420806.
      View in: PubMed   Mentions:
    80. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 01 15; 24(2):334-340. Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ. PMID: 29089357; PMCID: PMC5771996.
      View in: PubMed   Mentions:
    81. A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clin Cancer Res. 2017 Dec 15; 23(24):7467-7473. Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR. PMID: 28954786; PMCID: PMC8788622.
      View in: PubMed   Mentions:
    82. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. 2018 Jan 01; 124(1):105-109. Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA. PMID: 28940498; PMCID: PMC5735028.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    83. Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer. 2017 10; 112:195-199. Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G. PMID: 29191595; PMCID: PMC8788626.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    84. Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. JCO Precis Oncol. 2017; 1. Hellmann MD, Hayashi T, Reva B, Yu HA, Riely GJ, Adusumilli PS, Travis WD, Wilkins O, Bramletta N, Chandramohan R, Fleischut MH, Kris MG, Robson ME, Arcila ME, Paik PK, Ladanyi M. PMID: 32913967; PMCID: PMC7446373.
      View in: PubMed   Mentions:
    85. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017 06; 108:109-114. Patel SH, Rimner A, Foster A, Zhang Z, Woo KM, Yu HA, Riely GJ, Wu AJ. PMID: 28625621; PMCID: PMC5477661.
      View in: PubMed   Mentions:
    86. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discov. 2017 06; 7(6):596-609. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ. PMID: 28336552; PMCID: PMC5482929.
      View in: PubMed   Mentions: 350     Fields:    Translation:Humans
    87. Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):e81-e83. Jakubowski CD, Plodkowski AJ, Chang JC, Rekhtman N, Iqbal A, Paik PK, Yu HA. PMID: 27863924; PMCID: PMC5490243.
      View in: PubMed   Mentions:
    88. A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. J Thorac Oncol. 2017 01; 12(1):102-109. Yu HA, Perez L, Chang Q, Gao SP, Kris MG, Riely GJ, Bromberg J. PMID: 27613527; PMCID: PMC5552054.
      View in: PubMed   Mentions:
    89. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. PLoS One. 2016; 11(1):e0146063. Li BT, Lou E, Hsu M, Yu HA, Naidoo J, Zauderer MG, Sima C, Johnson ML, Daras M, DeAngelis LM, Fleisher M, Kris MG, Azzoli CG. PMID: 26730601; PMCID: PMC4701719.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    90. Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2016 Mar 01; 22(5):1103-10. Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA. PMID: 26446944; PMCID: PMC4775471.
      View in: PubMed   Mentions: 198     Fields:    Translation:HumansCellsCTClinical Trials
    91. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol. 2015 Oct; 1(7):982-4. Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, Ladanyi M. PMID: 26181354; PMCID: PMC4665629.
      View in: PubMed   Mentions:
    92. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res. 2015 May 15; 21(10):2221-6. Riely GJ, Yu HA. PMID: 25979928; PMCID: PMC4435716.
      View in: PubMed   Mentions:
    93. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Clin Oncol. 2015 May 20; 33(15):1666-73. Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ. PMID: 25870087; PMCID: PMC4881377.
      View in: PubMed   Mentions:
    94. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Cancer. 2015 Jun 15; 121(12):2078-82. Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, Riely GJ, Kris MG. PMID: 25781862; PMCID: PMC4783794.
      View in: PubMed   Mentions:
    95. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3):431-7. Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. PMID: 25415430; PMCID: PMC4479120.
      View in: PubMed   Mentions:
    96. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res. 2014 Dec 01; 20(23):5898-907. Yu HA, Riely GJ, Lovly CM. PMID: 25303979; PMCID: PMC4253858.
      View in: PubMed   Mentions:
    97. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014 Jun; 9(6):892-6. Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, Kris MG, Rekhtman N, Ladanyi M, Wang L, Berger MF, Pietanza MC. PMID: 24828667; PMCID: PMC4199745.
      View in: PubMed   Mentions:
    98. Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol. 2014 Apr; 9(4):554-8. Yu HA, Arcila ME, Harlan Fleischut M, Stadler Z, Ladanyi M, Berger MF, Robson M, Riely GJ. PMID: 24736080; PMCID: PMC4412273.
      View in: PubMed   Mentions:
    99. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):322-9. Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ. PMID: 24679729; PMCID: PMC5691362.
      View in: PubMed   Mentions:
    100. Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. Nat Rev Clin Oncol. 2013 Oct; 10(10):551-2. Yu HA, Pao W. PMID: 23959269; PMCID: PMC4665630.
      View in: PubMed   Mentions:
    101. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15; 19(8):2240-7. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. PMID: 23470965; PMCID: PMC3630270.
      View in: PubMed   Mentions:
    102. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013 Mar; 8(3):346-51. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. PMID: 23407558; PMCID: PMC3673295.
      View in: PubMed   Mentions:
    103. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):161-9. Yu HA, Riely GJ. PMID: 23411383; PMCID: PMC3673302.
      View in: PubMed   Mentions:
    104. Who should receive EGFR tyrosine-kinase inhibitors? Lancet Oncol. 2012 Nov; 13(11):1074-6. Yu HA, Riely GJ. PMID: 23078959.
      View in: PubMed   Mentions:
    Helena's Networks
    Concepts (270)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (18)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California